Lupin appoints Ms Christine Mundkur as an Independent Director Kumar Jeetendra | April 1, 2019 Mumbai, April 1, 2019: Pharma major Lupin Limited (Lupin) announced today the appointment of Ms. Christine Mundkur as an Independent Director with immediate effect. Ms. Mundkur most recently served as Chief Executive Officer and Non-voting Chairman of the Board of Directors for Impopharma Inc, a developer of complex formulations focused on inhalation pharmaceutical products. While …
Lupin Bioresearch Centre completes fifth successful US FDA inspection Kumar Jeetendra | April 3, 2019 Mumbai, Baltimore, April 03, 2019: Pharma major Lupin Limited (Lupin) announced the successful completion of the United States Food and Drug Administration (U.S. FDA) inspection at its Lupin Bioresearch Centre (LBC) without any observations. rnrnThis is the fifth successive inspection without any 483 observations, indicating superior quality compliance maintained at this global bioresearch facility. rnrnLupin …
Emcure launches worlds first generic Eribulin for treatment of metastatic breast cancer Kumar Jeetendra | April 4, 2019 Eribulin will be available in India at approximately 40% cost of the innovator brand Emcure Pharmaceuticals, a leading integrated global pharmaceutical company from India today announced the launch of the world’s first generic version of Eisai Pharmaceutical’s Halaven (Eribulin) for the treatment of metastatic breast cancer (MBC). Emcure will be marketing the drug under brand …
Microbioz India launched online platform for Hospitals and Medical equipments Kumar Jeetendra | April 6, 2019 Delhi, 4 April 2019: Microbioz India- a Leading B2B Publication for Bio-Pharma and Analytical Industry is launched a new platform to serve Medical & Healthcare industry through www.microbiozhealth.com Microbioz India has become a well-known brand for offering best promotional plan with amazing servicing to the clienteles. they are a leading name into the laboratory and …
Elemental Impurity analysis in Pharmaceutical Products Plasma Spectroscopy in Pharma A Primer Kumar Jeetendra | April 8, 2019 It’s the duty and responsibility of the manufacturer to ensure that a pharmaceutical product is having the right dose of the lifesaving drug and free from any form of unwanted and harmful contaminants. Health agenesis like FDA regulate the pharmaceutical market by issuing guide linesfor identity, strength, quality and purity of drug products and their …
The analytical and laboratory industry gears up for analytica Anacon India and India Lab Expo in Mumbai Kumar Jeetendra | April 9, 2019 The analytical and laboratory industry gears up for analytica Anacon India and India Lab Expo in Mumbai rn1. Strong domestic and international participation
Sun Pharma transfers local business to new subsidiary from AML Kumar Jeetendra | April 10, 2019 On Monday 8th April 2019, India’s largest drug maker Sun Pharma has closed their transactions with the Altas Global Trading and it has transferred their domestic distribution business to a wholly owned subsidiary from Aditya Medisales (AML). The Sun Pharma Distributors (SPDL), will be incorporated from April 2019, and the distribution of the Sun’s formulation …
Lupin launches Fluoxetine Tablets USP Kumar Jeetendra | April 10, 2019 Mumbai, Baltimore, April 10, 2019: Pharma major Lupin Limited (Lupin) announced the launch of Fluoxetine Tablets USP, 60mg, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Fluoxetine Tablets USP, 60mg, is the generic version of Alvogen Group Holdings 3 LLC’s Fluoxetine Tablets, 60mg. It is indicated in the …
Lupin receives FDA approval for Testosterone Gel Kumar Jeetendra | April 11, 2019 Mumbai, Baltimore, April 11, 2019: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), from the United States Food and Drug Administration (FDA) to market a generic version of AbbVie, Inc’s (AbbVie) AndroGel 1.62%. Lupin’s Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), …
Dr Reddys Laboratories announces acquisition of ANDA portfolio Kumar Jeetendra | April 13, 2019 Hyderabad, India and Princeton, NJ, USA. April 13,2019- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced todaythat it has entered into a definitive agreement to acquire aportfolio of 42 approved,non-marketed Abbreviated New Drug Applications (ANDAs) in the U.S. The portfolio includes more …
Cipla launches Niveoli TM Indias first extrafine ICSLABA combination HFA inhaler Kumar Jeetendra | April 13, 2019 Mumbai, April 12, 2019 – Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announces that it has launched Niveoli™, India’s first extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults, targeting drug delivery to the small airways. Niveoli™ is a proprietary Cipla inhaler, and the latest offering from Cipla in …
Cipla appoints Dr Raju Mistry as Global Chief People Officer Kumar Jeetendra | April 22, 2019 Mumbai, April 22, 2019 – Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announces the appointment of Dr. Raju Mistry as President and Global Chief People Officer (GCPO) of Cipla. Raju is an accomplished and veteran Human Resources (HR) leader with over 27 years of global experience across diverse sectors …
